Accueil・Liste d'Actions・Veracyte Inc

Veracyte Inc

Fermé

SecteurSoins de santé

46.18 3.52

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

43.07

Max

46.51

Chiffres clés
By Trading Economics
Revenu	-20M 29M
Ventes	-1.6M 139M
P/E Moyenne du Secteur	51.491 64.641
BPA	0.52
Marge bénéficiaire	20.642
Employés	755
EBITDA	-11M 35M

Recommandations
By TipRanks
Recommandations	Achat
Prévisions sur 12 Mois	+27.34% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	1.8B 4.4B
Ouverture précédente	42.66
Clôture précédente	46.18

Veracyte Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

4 août 2026, 19:36 UTC

News

Correlated Moves

Veracyte shares are rising as Piper Sandler and Stephens maintain Overweight ratings, despite lowering price targets to $54 and $55, respectively.

3 août 2026, 20:06 UTC

Veracyte Inc's shares are lower today, diverging from broader market gains amid high trading volume. No specific news was identified to explain the decline.

1 août 2026, 00:01 UTC

Veracyte Inc is trading lower in after-market hours, reflecting broader market declines. Shares remain near the lower end of their one-month range.

31 juil. 2026, 20:02 UTC

News

Social Media

Veracyte Inc shares are lower despite positive analyst outlooks and target increases from Freedom and Needham following a recent earnings report that exceeded expectations.

30 juil. 2026, 23:21 UTC

News

Social Media

Veracyte shares fell in after-market trading despite reporting second-quarter revenue of $150.3 million and adjusted EPS of $0.54, exceeding expectations.

29 juil. 2026, 19:47 UTC

Macro Event

Veracyte Inc's shares are advancing as the Federal Reserve maintains interest rates. The decision aligns with market expectations amid ongoing economic expansion.

28 juil. 2026, 15:22 UTC

Veracyte Inc. shares are higher today, supported by broader strength in biotechnology stocks. No specific news was identified to explain the price movement.

27 juil. 2026, 20:14 UTC

Veracyte Inc shares are higher in after-market trading, despite no specific news. Broader market sentiment may be affected by declining crude oil prices.

24 juil. 2026, 22:16 UTC

Correlated Moves

Veracyte Inc shares declined during after-market hours, reflecting broader weakness in the biotechnology sector. The stock shifted toward the lower end of its one-month trading range.

22 juil. 2026, 20:13 UTC

Correlated Moves

Veracyte Inc shares are lower in after-market trading, reflecting broader market declines amid rising crude oil prices and geopolitical tensions.

21 juil. 2026, 17:16 UTC

Correlated Moves

Veracyte Inc shares are higher today, recovering after three days of declines. The stock is now above its 20-day moving average.

20 juil. 2026, 20:01 UTC

Correlated Moves

Veracyte Inc shares declined sharply today, marking three consecutive lower sessions amid broader market weakness and heightened volatility related to geopolitical tensions.

Comparaison

Variation de prix

Veracyte Inc prévision

Objectif de Prix

By TipRanks

27.34% hausse

Prévisions sur 12 Mois

Moyen 57.11 USD 27.34%

Haut 70 USD

Bas 44 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

Achat

Maintien

Vente

Basé sur 11 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Veracyte Inc

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.